Nialamide

Nialamide
Clinical data
AHFS/Drugs.com International Drug Names
Routes of
administration
Oral
ATC code N06AF02 (WHO)
Legal status
Legal status
  • AU: S4 (Prescription only)
Identifiers
CAS Number 51-12-7 YesY
PubChem (CID) 4472
DrugBank DB04820 YesY
ChemSpider 4317 YesY
UNII T2Q0RYM725 YesY
KEGG D07337 YesY
ECHA InfoCard 100.000.073
Chemical and physical data
Formula C16H18N4O2
Molar mass 298.34 g/mol
3D model (Jmol) Interactive image
  (verify)

Nialamide (Niamid, Niamide, Nuredal, Surgex) is a non-selective, irreversible monoamine oxidase inhibitor (MAOI) of the hydrazine class that was used as an antidepressant.[1] It was withdrawn by Pfizer several decades ago due to the risk of hepatotoxicity.[2][3]

The antiatherogenic activity of nialamide was used to design pyridinolcarbamate.[4]

See also

References

  1. William Andrew Publishing (1 December 2006). Pharmaceutical Manufacturing Encyclopedia, 3rd Edition. Elsevier. pp. 2935–. ISBN 978-0-8155-1856-3.
  2. Shayne C. Gad (26 April 2012). Safety Pharmacology in Pharmaceutical Development: Approval and Post Marketing Surveillance, Second Edition. CRC Press. pp. 138–. ISBN 978-1-4398-4567-7.
  3. Edward Shorter (28 September 2008). Before Prozac : The Troubled History of Mood Disorders in Psychiatry: The Troubled History of Mood Disorders in Psychiatry. Oxford University Press. pp. 137–. ISBN 978-0-19-970933-5.
  4. https://books.google.co.uk/books?id=a1bmCAAAQBAJ&pg=PA387#v=onepage&q&f=false
This article is issued from Wikipedia - version of the 9/2/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.